IMMX peer analysis
Immix Biopharma (IMMX) against its competitors: price, today's move, 1-year return and market value side by side.
IMMX and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ABVX Abivax | $85.75 | 1.87% | -14.64% | $7.83B |
| CLDX Celldex Therapeutics | $30.00 | 6.12% | 18.41% | $2.35B |
| CRDF Cardiff Oncology | $0.76 | -13.07% | -60.86% | $67.60M |
| CTMX CytomX Therapeutics | $2.19 | 2.34% | -48.17% | $512.06M |
| IMMP Immutep | $2.69 | -8.81% | -92.59% | $21.74M |
| IMUX Immunic | $7.64 | 4.37% | 6.50% | $108.34M |
| MGNX MacroGenics | $2.33 | 4.95% | 54.14% | $147.15M |
| NBP NovaBridge Biosciences | $0.91 | -10.09% | -76.35% | – |
| NRIX Nurix Therapeutics | $15.07 | 1.55% | 21.94% | – |
| RCUS Arcus Biosciences | $18.28 | 3.34% | -10.79% | $2.46B |
| IMMX Immix Biopharma | $7.99 | 10.97% | 114.71% | – |
- IMMX's peers: ABVX (Abivax), CLDX (Celldex Therapeutics), CRDF (Cardiff Oncology), CTMX (CytomX Therapeutics), IMMP (Immutep), IMUX (Immunic), MGNX (MacroGenics), NBP (NovaBridge Biosciences).
Updated 2026-11-07 11:54 UTC